IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market
POTOMAC, MD / ACCESS Newswire / May 22, 2025 / IGC Pharma, Inc. ('IGC', or the 'Company') (NYSE American:IGC) today announced a clinical trial site at Santa Cruz Behavioral in Puerto Rico for its CALMA Phase 2 clinical trial, investigating IGC-AD1 for agitation in Alzheimer's disease. This strategic site directly addresses the significant impact of Alzheimer's in the region.
Approximately 12.5% of Puerto Ricans over the age of 65 have Alzheimer's, a figure notably higher than the roughly 10% prevalence observed in older non-Hispanic white populations in the U.S. This disparity is influenced by factors such as Puerto Rico's rapidly aging demographic and unique genetic predispositions. The heightened prevalence translates into a substantial economic burden, with medical care for dementia in Puerto Rico accounting for over a quarter of total societal healthcare costs, a proportion higher than in the continental U.S.
'We're pleased to work with Santa Cruz Behavioral ('SCB') as a trial site for our CALMA study, expanding our reach in Puerto Rico alongside a previously announced site at the University of Puerto Rico,' said Ram Mukunda, CEO of IGC Pharma. 'Puerto Rico represents a high-need and underserved population in Alzheimer's care, and SCB strengthens our ability to evaluate IGC-AD1 across diverse patient populations. Diversity in clinical trials not only improves scientific validity but also supports broader regulatory and commercial success.'
For IGC Pharma's investors, this initiative represents a strategic imperative. By engaging a vast, underserved market with a high disease prevalence, diverse clinical trials are not only ethically sound but also enhance the commercial viability of therapies by ensuring universal effectiveness.
Santa Cruz Behavioral in Puerto Rico, known for its outstanding mental healthcare services from a biopsychosocial perspective, serves as a key partner in this endeavor.
Patients and caregivers interested in participating in the CALMA trial should please contact Santa Cruz Behavioral in Bayamon Puerto Rico.
About IGC-AD1 and the CALMA Trial
IGC-AD1 is IGC Pharma's investigational cannabinoid-based therapy currently in a Phase 2 multicenter, double-blind, randomized, placebo-controlled study (CALMA) evaluating its safety and efficacy for treating agitation in Alzheimer's dementia. Agitation affects up to 76% of Alzheimer's patients, often leading to increased hospitalization and caregiver burden. IGC-AD1 acts as a partial CB1 receptor agonist with anti-neuroinflammatory properties, targeting key pathways involved in neuroinflammation, oxidative stress, and neurotransmitter imbalances.
For more information on the CALMA trial, visit: ClinicalTrials.gov.
About IGC Pharma (dba IGC):
IGC Pharma (NYSE American:IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, IGC-AD1, is a cannabinoid-based therapy currently in a Phase 2 trial ( CALMA ) for agitation in Alzheimer's dementia. Our pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. We integrate AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. With 30 patent filings and a commitment to innovation, IGC Pharma is advancing breakthrough therapies.
Forward-Looking Statements:
This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma's expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma's control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company's failure or inability to commercialize one or more of the Company's products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA's general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma's U.S. Securities and Exchange Commission ('SEC') filings. IGC incorporates by reference its Annual Report on Form 10-K filed with the SEC on June 24, 2024, and on Form 10-Qs filed with the SEC on August 7, 2024, November 12, 2024, and February 14, 2025, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.
Contact Information
Rosalyn Christian
IMS Investor Relations
[email protected]
(203) 972-9200
SOURCE: IGC Pharma, Inc.
press release
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Can adults grow new brain cells?
When you buy through links on our articles, Future and its syndication partners may earn a commission. The developing human brain gains billions of neurons while in the womb, and tacks on some more during childhood. For most of the 20th century, the conventional wisdom was that the brain cells grown before adulthood would be the only ones we would have for the rest of our lives. But over the past few decades, more and more research is challenging that belief. So is it actually possible for adults to grow neurons? While some experts believe there's strong evidence that we can gain brain cells after childhood, others are still skeptical of this notion. The process of creating new brain cells is called neurogenesis. Researchers first observed neurogenesis after birth in lab animals of various ages, including mice, rats and songbirds. In adult mice, they found new neurons growing in parts of the brain collectively called the subventricular zone, an area closely linked with sense of smell, as well as in the hippocampus, a structure that's central to memory. Researchers think that neurogenesis in these brain regions is important for plasticity, or the brain's ability to adapt and change over time. Plasticity underlies the ability to learn and form memories, for instance. In mice, it's clear that lifestyle factors such as living in a stimulating environment and exercising can promote the growth of new neurons. Conversely, in mouse models of diseases like Alzheimer's, neurogenesis is hampered. What's still up for debate is whether these findings extend beyond mice and other lab animals. "Most of our knowledge about adult neurogenesis came from studies in animal models," Hongjun Song, a professor of neuroscience at the University of Pennsylvania Perelman School of Medicine, told Live Science in an email. "Whether such knowledge can be directly translated to human studies is a challenge." That's because many of the studies that have established the existence of adult neurogenesis in animals used methods that aren't possible in human studies, such as injecting radioactive tracer molecules into the brain. These methods enable scientists to visualize if and where new neurons are growing, but the tracers themselves can be toxic. These methods also require dissecting the brain after the animal has been euthanized. "Unfortunately, there is no way to measure neurogenesis in the living person yet," Gerd Kempermann, a professor of genomics of regeneration at the Center for Regenerative Therapies in Dresden, Germany, told Live Science in an email. Related: Is there really a difference between male and female brains? Emerging science is revealing the answer. There are, however, some rare cases in which scientists have been able to apply similar methods to track neurogenesis in humans. For example, the radioactive tracer molecules used in animal neurogenesis studies are also sometimes used by doctors to track tumor growth in patients with brain cancer. While these radioactive tracer molecules are too toxic to give to healthy people, their benefits outweigh their risks in patients who already have cancer. Scientists behind a 1998 study published in the journal Nature Medicine used this approach and analyzed the brains of cancer patients after their deaths. They reported that, in addition to flagging cancer cells, the tracer molecules had marked new neurons in the hippocampus. This finding suggested that humans could grow new neurons well into adulthood, given the patients were 57 to 72 years old. Later, a 2013 study in the journal Cell used a form of radiocarbon dating to look for new neurons in humans. Radiocarbon dating usually determines the age of a sample by comparing the relative proportion of two different forms of carbon, or carbon isotopes, called carbon-14 and carbon-12. But to study neurogenesis in humans, scientists instead looked at carbon-14 concentrations inside the DNA of cells. Their approach took advantage of the fact that there was a spike in carbon-14 levels in the atmosphere caused by nuclear bomb tests in the 1950s and 1960s. People's bodies absorbed this carbon-14 via their diets, and it became incorporated into their DNA. The amount of carbon-14 in a given cell corresponds to the isotope's concentrations in the atmosphere at the time the cell formed, making it possible to roughly pinpoint the "birthday" of that cell — and determine whether it formed after its owner's birth. By analyzing postmortem brain tissue from people ages 19 to 92, this radiocarbon study identified newborn neurons in the adult hippocampus. But while compelling, the study's methods were so complex that the results have never been replicated. That said, there are also more indirect markers of neurogenesis, such as certain proteins that are only present in growing neurons. Using these methods, both Kempermann and other research groups have uncovered additional evidence of newborn neurons in the adult human brain. "There are many different markers that are more or less specific for adult neurogenesis," Kempermann said. "In tissue sections, one can study these markers under the microscope and look for patterns that are consistent with neuronal development." But some researchers aren't convinced by this evidence. Arturo Alvarez-Buylla, a professor of neurological surgery at the University of California, San Francisco, has spent his career studying the growth of new neurons. While he's observed new neurons being formed in children and adolescents, he's found little evidence to support the notion of neurogenesis in adults. Alvarez-Buylla believes there are a number of issues that may lead other researchers to find signs of neurogenesis in adult humans. For example, the chemical markers that some labs use to track new neurons may also show up in other cell types, such as glia, which are cells in the brain that support neurons' function in various ways. This may make it appear that new neurons are growing when they're actually not. He's also skeptical of the use of carbon-14 dating for this purpose, calling it "creative" but arguing that researchers can't confirm that the new cells are neurons, or if there could be other potential reasons for varying carbon-14 levels in cells. But Alvarez-Buylla isn't ruling out the possibility of human adult neurogenesis; he's only saying that — so far — the evidence hasn't convinced him. "I would say that is a rare phenomenon," said Alvarez-Buylla. "If it happens, it's very, very few cells." Kempermann, on the other hand, is a firm believer that people can grow new neurons well into adulthood. "The positive reports outnumber the critical papers by far, their take is much wider, and their quality is overall higher." The researchers said that understanding whether adult neurogenesis exists will continue to be a key question for the field of neuroscience. RELATED STORIES —Could we ever retrieve memories from a dead person's brain? —What happens in your brain while you sleep? —How much of your brain do you need to survive? "The question about whether adults can grow new neurons has tremendous implications for the plasticity of the adult brain," Song said. If new neurons can be grown and integrated into the brain, he explained, those mechanisms could form the basis for new therapies for a variety of conditions, including brain injuries and neurodegenerative disorders. Alvarez-Buylla said that even if he doesn't believe neurogenesis happens frequently in adults, it may nonetheless be possible to harness the mechanisms used by animals to grow new neurons for human therapies. "The whole idea that it can happen opens a huge door for repair," he said. "I hope that we can keep our plasticity open to things going either way."
Yahoo
a day ago
- Yahoo
Getting help: neurodiversity, aging, addiction and mental illness
The National Institute of Mental Health counts mental illnesses among common maladies not just in the U.S., but around the world, estimating that as much as 23% of the adult U.S. population faces mental challenges. Approximately 53 million Americans are family caregivers, providing varying degrees of support to relatives and loved ones because of disease, disability or simple frailty. Last October, the Columbia University Mailman School of Public Health and Otsuka America Pharmaceutical did a study that concluded that if family caregiving was a business, 'it would be the largest revenue-generating company in the world,' providing $873.5 billion worth of labor each year. Close to 40% of that is due to Alzheimer's disease or dementia care, though only a quarter of those caregivers face that particular challenge. Neurodiversity, addiction, aging and mental health are all issues with some challenges where families may find they need some help or suggestions or simply access to a support group. A few weeks ago, a team of Deseret News reporters set out to explore some of the issues impacting families across that spectrum of issues. Today, we offer those stories with links in case you missed them earlier. The importance of sensory awareness with autism Learning disorders and decades of progress Attention deficit/hyperactivity disorder and new approaches Why caregivers can't do it all alone Aging well: preserving your brain with food, exercise and sleep What we're learning about Alzheimer's disease Anxiety and depression are very, very old problems How states are tackling social media and smartphone use in schools What do you do with debilitating fear? Healing addiction through power of community, compassion and hope. How addiction impacts the brain
Boston Globe
2 days ago
- Boston Globe
An expensive Alzheimer's lifestyle plan offers false hope, experts say
Kerry Briggs was taking them all because a doctor had told her that with enough supplements and lifestyle modifications, her Alzheimer's symptoms could not only be slowed, but reversed. It is an idea that has become the focus of television specials, popular podcasts, and conferences; the sell behind mushroom supplements and self-help books. Advertisement But the suggestion that Alzheimer's can be reversed through lifestyle adjustments has outraged doctors and scientists in the medical establishment, who have repeatedly said that there is little to no proof for such a claim and expressed concern that the idea could harm a large group of vulnerable Americans. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up John Briggs had come across the idea after learning about Dale Bredesen, who had been performing a series of small and unconventional studies through which he claimed to have designed a set of guidelines to reverse Alzheimer's symptoms. 'Very, very few people should ever get this,' Bredesen told an audience in July, referring to cognitive decline. His company has made bracelets with the phrase 'Alzheimer's Is Now Optional' on them. His pitch has gained a following. Bredesen's 2017 book, 'The End of Alzheimer's,' has sold around 300,000 copies in the United States and became a New York Times bestseller. Advertisement A day's worth of supplements for Kerry Briggs, diagnosed with early-onset Alzheimer's. JAMIE KELTER DAVIS/NYT Many doctors encourage Alzheimer's patients to modify their diets and exercise regimens in hopes of slowing the disease's progress, said Dr. Bruce Miller, director of the Memory and Aging Center at the University of California San Francisco. 'The question, though, of reversal is very different.' 'It's one thing to say that you're reversing an illness because someone says they feel better and another to prove it,' Miller said. 'We don't have the proof.' Bredesen, 72, was once also a top neurologist at the University of California San Francisco, but he has not had an active medical license for much of the past three decades and doesn't see patients anymore. He became skeptical of the medical and pharmaceutical industries' approach to treating Alzheimer's and dedicated himself to an alternative method focused on food, supplements, lifestyle tweaks, and detoxification treatments. The central idea was that there was no 'silver bullet' -- no one pill or intervention -- that could cure Alzheimer's. Instead, Bredesen believed in firing a 'silver buckshot' (a reference to the sprayed pellets that come out of shotgun shells) by modifying 36 factors simultaneously. His strict protocol could be personalized after extensive lab testing but generally involved a low-carbohydrate diet, intermittent fasting, supplements and, at times, interventions such as hormone treatments and home mold remediation. For the Briggses, who live in North Barrington, Ill., the adjustments did not come cheap: $1,000 a month for supplements, $450 per hour for a specialty doctor and other costs, which altogether added up to $25,000 over eight months. Advertisement But Kerry Briggs wanted to do something to help find a treatment for the disease, and John Briggs wanted to help his wife. More than 7 million people in the United States -- roughly 11 percent of those 65 and older -- have Alzheimer's, the world's leading cause of dementia. Despite decades of research and the development of a few medications with modest benefits, a cure for the disease has remained elusive. The Alzheimer's Association, which helped fund Bredesen's earlier and more conventional research, sees his recent approach as insufficiently rigorous. His trials have suggested his protocol can improve cognition, but Maria Carrillo, the organization's chief science officer, said they 'fall short of what the research community' would consider convincing enough to suggest to patients, since they lack control groups and are small, with the number of participants ranging from 10 to 25. Others have expressed similar unease. In 2020, Dr. Joanna Hellmuth, then a neurologist at the University of California San Francisco, published an article in The Lancet Neurology pointing to a number of 'red flags' within Bredesen's studies, including 'the substantial potential for a placebo effect.' Dr. Jason Karlawish, co-director of Penn Memory Center at the University of Pennsylvania, said Bredesen's research and recommendations don't adhere to the standards of medicine. The Alzheimer Society of Canada has gone so far as to say Bredesen is offering 'false hope.' Bredesen maintains that the results of his program can be remarkable, though he acknowledges it's less successful for people with more noticeable symptoms: 'It amazes me how people fight back against something that's actually helping,' Bredesen said. Advertisement He connected The New York Times with patients who said they had benefited from his recommendations. Sally Weinrich, 77, in South Carolina, said she used to forget her pocketbook or miss the school pickup window for her grandchildren, but now thinks more clearly. Darrin Kasteler, 55, in Utah, who had struggled to tie a necktie and to drive, said both had become easier. To Bredesen's supporters, the testimonials are evidence of promise. But what divides Bredesen from the medical establishment isn't his emphasis on lifestyle adjustments; it is the boldness of his claims, his unconventional and strict treatment plan, and the business he is building around both. It was one of Kerry Briggs' sisters, Jennifer Scheurer, who first noticed that something was off. In 2021, while visiting Scheurer in Oregon, Briggs repeated the same story a few times in one day, and had trouble finding words and playing board games. Scheurer also found Briggs standing in her kitchen, seemingly lost. This was particularly odd; Briggs was an architect, and she had designed the kitchen herself. Briggs underwent a series of tests, ending in a spinal tap, which showed evidence of Alzheimer's. She was 61. The news was devastating, but Briggs told her husband that she wanted to enroll in a clinical trial to help others. But none of the trials admitted her. She weighed too little, and her disease was already too advanced. Then a friend recommended 'The End of Alzheimer's.' John Briggs read that book and a follow-up, 'The First Survivors of Alzheimer's.' Excited, he reached out to Bredesen's company, Apollo Health, to see what could be done for his wife. Bredesen had developed a paid plan called 'Recode,' a portmanteau of the phrase 'reversal of cognitive decline,' and a training program for health practitioners like medical doctors, chiropractors and naturopaths to learn to implement it. On the Apollo Health website, Bredesen's program is advertised as the 'only clinically proven program to reverse cognitive decline in early stage Alzheimer's disease.' Advertisement In January 2024, John Briggs paid an $810 fee to join Apollo Health, which gave Kerry Briggs access to a personalized plan and matched her with Dr. Daniel LaPerriere, a doctor in Louisville, Colo. On LaPerriere's recommendation, the Briggses began to eat a modified keto diet that was low in sugar and rich in plants, lean protein, and healthy fats. The Briggses were not allowed most fruit -- no apples, bananas, peaches or grapes ('all these things that we love,' John Briggs said), though the couple made an exception for blueberries. To see if Kerry Briggs was in a metabolic state of ketosis, where fat is used for energy instead of carbohydrates, John Briggs experimented with pricking her finger twice each day to test her blood. In keeping with Bredesen's general guidelines, Kerry Briggs began working with a therapist to manage stress and tried the brain-training games the protocol recommended, though she struggled to play them. LaPerriere gave John Briggs the unconventional instruction to collect dust samples at home in order to determine whether 'toxic mold' was present (only trace amounts were) and ordered lab tests to see if Kerry Briggs was suffering from an inability to flush it from her organs (she wasn't). He also prescribed Briggs hormone-replacement therapy, in the hope of improving her cognition. Advertisement Briggs' primary-care physician raised concerns about the risks, John Briggs said, but she took the hormones anyway. Briggs understood that the protocol would be unlikely to restore Kerry Briggs to her former self. But he was determined to see it through for at least six months. By last September, though, John Briggs was struggling to notice many benefits. Kerry Briggs could no longer keep track of conversations with her therapist, who suggested they stop the sessions. The next month, John Briggs began touring memory-care facilities for his wife. In February, after about eight months, they quit the protocol altogether. Bredesen said that he rarely tells people not to try his program, even if the chance of helping is small, because of the possibility of improvement. But he considered Kerry Briggs' experience 'not representative' of the results he has achieved in trials and said in retrospect that 'you could kind of tell ahead of time' that she would not fare well. Bredesen has urged prospective patients to start his program preventively or early in the disease's progression. Helping patients already experiencing significant decline, like Briggs, is difficult, he and LaPerriere said. 'People are more incentivized to come in when they're farther along,' Bredesen said. 'And that's a real dilemma, which is why we're telling people, 'Please do not wait because we can do so much more.'' This article originally appeared in
